After a mean follow-up of 10.5 months , the primary endpoint occurred in 92 patients ( 18.2 % ) in the eplerenone group and in 149 patients ( 29.4 % ) in the placebo group [ adjusted hazard ratio ( HR ) , 0.58 ; 95 % confidence interval ( CI ) , 0.45-0 .76 ; P < 0.0001 ] .